PROTAGONIST THERAPEUTICS INC's ticker is PTGX and the CUSIP is 74366E102. A total of 129 filers reported holding PROTAGONIST THERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is 4.22 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q4 2022 | $237,511 | -63.3% | 21,770 | -71.7% | 0.00% | -66.7% |
Q3 2022 | $648,000 | +50.0% | 76,862 | +40.6% | 0.00% | +50.0% |
Q2 2022 | $432,000 | +32.1% | 54,676 | +295.9% | 0.00% | +100.0% |
Q1 2022 | $327,000 | -84.2% | 13,810 | -77.2% | 0.00% | -80.0% |
Q4 2021 | $2,069,000 | +506.7% | 60,490 | +258.1% | 0.01% | +66.7% |
Q4 2020 | $341,000 | -90.0% | 16,893 | -85.7% | 0.00% | -94.5% |
Q2 2020 | $3,414,000 | +1203.1% | 118,120 | +218.5% | 0.06% | +685.7% |
Q1 2020 | $262,000 | -60.1% | 37,083 | -60.2% | 0.01% | +75.0% |
Q4 2019 | $656,000 | -35.0% | 93,103 | +10.8% | 0.00% | -55.6% |
Q3 2019 | $1,009,000 | -18.6% | 84,034 | -17.9% | 0.01% | -25.0% |
Q2 2019 | $1,239,000 | +120.1% | 102,337 | +128.5% | 0.01% | +100.0% |
Q1 2019 | $563,000 | +223.6% | 44,777 | +73.5% | 0.01% | +200.0% |
Q4 2018 | $174,000 | -53.2% | 25,804 | -28.5% | 0.00% | -50.0% |
Q3 2018 | $372,000 | +14.1% | 36,110 | -25.5% | 0.00% | 0.0% |
Q2 2018 | $326,000 | +129.6% | 48,467 | +193.2% | 0.00% | +100.0% |
Q1 2018 | $142,000 | – | 16,531 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
JOHNSON & JOHNSON | 2,449,183 | $20,647,000 | 6.08% |
Bain Capital Life Sciences Investors, LLC | 2,260,572 | $19,057,000 | 2.28% |
Kynam Capital Management, LP | 519,212 | $4,377,000 | 0.92% |
RTW INVESTMENTS, LP | 4,176,837 | $35,211,000 | 0.81% |
Tri Locum Partners LP | 199,500 | $1,682,000 | 0.46% |
Birchview Capital, LP | 38,000 | $320,000 | 0.22% |
Gratus Capital, LLC | 206,113 | $1,738,000 | 0.18% |
FARALLON CAPITAL MANAGEMENT LLC | 3,651,887 | $30,785,000 | 0.17% |
PDT Partners, LLC | 126,038 | $1,063,000 | 0.16% |
FOX RUN MANAGEMENT, L.L.C. | 40,683 | $343,000 | 0.13% |